Genzyme, a global biotechnology company, is launching a program to develop therapies for neglected diseases (such as malaria, tuberculosis), giving intellectual property. This event aims to address a disease that partnership, and which markets have decided to fund management. But a more serious problem, as the program is developed in the framework of corporate social responsibility umbrella Genzyme role fits into the global competitive strategy. "Hide
by Christopher A. Bartlett, Tarun Khanna, Prithwiraj Chowdhury Source: Harvard Business School 23 pages. Publication Date: August 20, 2009. Prod. #: 910407-PDF-ENG
Related Case Solutions & Analyses:
An ERP Story: Background (A)
Singapore Airlines: Global Challenges
Monsanto and the Monarch Butterfly
Note on Human Behavior: Reason and Emotion
Hutton Branch Manager (D)
Renault-Volvo Strategic Alliance A: March 1993
Time Out: A New Global Strategy to Bring Back Profit
PowerTech India: Redesigning Workforce Composition
Tokyo Electron: The Competitive Consolidation and Antitrust Challenge
Uber and the Ethics of Sharing: Exploring the Societal Promises and Responsibilities of the Sharing Economy Award winner Prize Winner
